Please assess the completion status of the following clinical trial:

Trial Title: Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary soft tissue sarcoma of the upper extremity (including shoulder) or lower extremity (including hip)~  * Incisional or core biopsy required within the past 8 weeks~* No histopathological diagnosis of any of the following:~  * Rhabdomyosarcoma~ * Extraosseous primitive neuroectodermal tumor (PNET)~ * Soft tissue Ewing sarcoma~ * Osteosarcoma~ * Kaposi sarcoma~ * Angiosarcoma~ * Aggressive fibromatosis (desmoid tumor)~ * Dermatofibrosarcoma protuberans~ * Chondrosarcoma~    * Extraskeletal myxoid chondrosarcoma allowed~* Tumor must be surgically resectable, as determined by a surgeon within the past 8 weeks~  * Limb-preservation surgery alone would not provide adequate local control, as determined by the surgeon~* No sarcoma of the hand, foot, head, neck, or intra-abdominal or retroperitoneal region or body wall~* No sarcoma ≥ 32 cm in any direction~* No lymph node or distant metastases, according to the following within the past 8 weeks:~  * History/physical examination, including a detailed description of the location, size, and stage of the sarcoma~ * MRI with contrast of the primary tumor~    * The maximum dimension of the primary tumor is measured in MRI images~ * CT scan of the chest~    * Multiple pulmonary nodules \< 8 mm without a histological diagnosis detected incidentally on a non-screening CT scan may be allowed~ * CT scan with contrast of the abdomen and pelvis in patients with intermediate- or high-grade sarcoma of the upper thigh~* No recurrent tumor after prior potentially curative therapy~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 8.0 g/dL (transfusion or other intervention allowed)~* Bilirubin ≤ 1.5 mg/dL\*~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2 times upper limit of normal\*~* Serum creatinine ≤ 1.6 mg/dL OR creatinine clearance ≥ 55 mL/min\*~* Left ventricular ejection fraction (LVEF) ≥ 50% by multiple gated acquisition scan (MUGA) or echocardiogram\*~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other invasive malignancy within the past 3 years, except nonmelanomatous skin cancer or carcinoma in situ of the breast, oral cavity, or cervix~* No severe, active co-morbidity, including any of the following\*:~  * Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months~ * Transmural myocardial infarction within the past 6 months~ * Acute bacterial infection or fungal infection requiring intravenous antibiotics~ * Acquired Immune Deficiency Syndrome (AIDS) or immunocompromised patients~    * HIV testing not required~* No NCI CTCAE v 3.0 grade 3-4 electrolyte abnormalities, including any of the following\*:~  * Calcium \< 7 mg/dL or \> 12.5 mg/dL~ * Glucose \< 40 mg/dL or \> 250 mg/dL~ * Magnesium \< 0.9 mg/dL or \> 3 mg/dL~ * Potassium \< 3mmol/L or \> 6 mmol/L~ * Sodium \< 130 mmol/L or \> 155 mmol/L NOTE: \*Applies to group 1 only, which was closed to accrual as of 01/08/10)~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior excisional biopsy in which the majority of the tumor (≥ 50%) is removed~* No prior radiotherapy to the region of the study cancer that would result in overlap of radiotherapy fields~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A - Chemotherapy (Type: EXPERIMENTAL): Radiation therapy with neoadjuvant or adjuvant or concurrent or interdigitated chemotherapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
- Cohort B - No Chemotherapy (Type: EXPERIMENTAL): Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete